EcoR1 Capital LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
EcoR1 Capital LLC
CRD #167121
SEC #801-100470
CIK #0001587114
AUM 3,424.7 M (2026-03-30)
Employees 22 (41% Investors, 0% Brokers)
Fees
Minimum
Phone415-754-3517
Address357 Tehama Street
San Francisco, CA 94103
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($B)
6.04.83.62.41.20.02010201520212027
In the News
Tue, 28 Jul 2026 EcoR1 Capital LLC Takes Position in Stoke Therapeutics, Inc. $STOK — MarketBeat
Tue, 28 Jul 2026 EcoR1 Capital LLC Cuts Stock Holdings in Xencor, Inc. $XNCR — MarketBeat
Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure]
Item 5.        Fees and Compensation

With respect to the Capital Funds, EcoR1 charges an annual management fee of 2.0% of each
investor’s capital account balance, which amount is payable in quarterly installments at the
beginning of each calendar quarter based on each investor’s capital account balance on that date.
EcoR1 also typically receives a performance-based allocation with respect to each investor equal
to 20% of net profits (including both realized and unrealized gains and losses) otherwise allocable
to such investor. Performance allocations are assessed in arrears on an annual basis (and on
withdrawals with respect to the amount withdrawn), and are only applied to the portion of profits
that exceed the cumulative losses previously allocated to or incurred by clients. EcoR1 complies
with Rule 205-3 under the Investment Advisers Act of 1940, to the extent required by applicable

law. Performance allocations and fees may create an incentive for EcoR1 to make more risky and
speculative investments than it would otherwise make.

Investors in the Venture Funds and the SPVs are all “qualified purchasers” as defined in Section
2(a)(51) of the Investment Company Act of 1940. As a result, detailed information regarding the
fees and compensation payable to EcoR1 and its affiliates by those funds is not required to be
provided herein. EcoR1 and its affiliates are entitled to management fees and performance-based
distributions from the Venture Funds that are calculated differently from the Capital Funds. EcoR1
does not receive a management fee from the existing SPV and the performance-based distributions
are calculated differently from the Capital Funds.

EcoR1 may waive or reduce all or any portion of the management or performance-based
allocations and distributions with respect to any investor or client.

EcoR1 deducts management fees and performance-based allocations and distributions directly
from client accounts.

To the extent that a client invests in mutual funds or ETFs, such client also bears indirectly the
investment advisory fees to the managers of those funds.

EcoR1 and its affiliates (including Mr. Nodelman) sit on company boards of directors or act as
consultants to companies, in which companies EcoR1’s clients may have invested or may invest
in the future. In such cases, EcoR1 or its affiliates may receive consideration for such services
(including cash and securities). EcoR1 will waive a portion of the management fees to which it
otherwise would be entitled in an amount equal to the value of such consideration. EcoR1 may
choose to value the securities (such as options or warrants) and apply the management fee waiver
as of the grant date, the exercise date or the date on which those securities are sold or become
freely tradable.

EcoR1 believes that its fees are competitive with fees charged by other investment advisers for
comparable services. Comparable services may be available, however, from other sources for
lower fees.

Relationships with EcoR1’s investment fund clients are terminable on the termination of the
applicable investment management agreement and, with respect to EcoR1’s investment
partnership clients, on expiration of the partnership’s term, dissolution of the partnership or on
EcoR1’s withdrawal as general partner. An investor in a Capital Fund may withdraw/redeem from
that fund over eight consecutive withdrawal/redemption dates, on specified prior written notice,
on the last day of any June or December beginning on or after the day preceding the first
anniversary of such investor’s admission to the fund. Investors in the Venture Funds and the SPVs
generally cannot withdraw from those funds but receive distributions when provided in the
governing documents for those funds.

In all cases, expenses, the pro rata portion of the management fee and the performance allocation
or fee through the date of termination are charged to the account. All prepaid but unearned
advisory fees are refunded on termination of a client’s account. An investor who withdraws from
a fund on a date other than the last day of a quarter or other appropriate period, however, does not
receive a refund of the management fee previously paid.

Each fund or other client is responsible for its own costs and expenses as detailed in the governing
documents for such fund. Such costs and expenses include, but are not limited to, trading costs
and expenses (such as brokerage commissions, expenses related to short sales, and clearing and
settlement charges), ongoing legal, accounting and bookkeeping fees and expenses, and the fees
and expenses charged by any fund administrator for its accounting, bookkeeping and other
services.

The Capital Funds and the Venture Funds will likely bear more than their pro rata share of
investment expenses (compared to the SPVs). For example, when EcoR1 identifies an investment
opportunity, it will incur research and other out-of-pocket expenses, and will allocate those
expenses between the Capital Funds and the Venture Funds on such basis as it determines fair and
equitable. If an SPV is subsequently established and participates in that investment opportunity,
that SPV may benefit from some or all of those earlier expenses without having to reimburse the
Capital Funds or the Venture Funds. If an investment opportunity for an SPV is identified but not
made, the Capital Funds and/or the Venture Funds would likely bear more than their pro rata share
of any “broken deal” expenses.

EcoR1 bears its own operating, general, administrative and overhead costs and expenses, other
than the expenses described above. All or part of these costs and expenses may be paid, however,
by securities brokerage firms and futures commission merchants that execute clients’ securities
trades, as discussed in Item 12 below.
Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure]
Item 7.        Types of Clients

EcoR1 provides investment advice to investment funds and may provide investment advice to
other accounts. Investors in the funds are required to invest a minimum of $25 million, but EcoR1
may waive this minimum. EcoR1 generally requires a minimum of $500 million to open an
individually managed account, but may waive this minimum. EcoR1’s separate account clients
may include high-net-worth individuals, institutions, trusts, endowments and pension plans.
Sector Form 13F Holdings Value ($B)
Zymeworks Inc 0.6
Anaptysbio Inc 0.4
Jazz Pharmaceuticals Inc 0.3
Crinetics Pharmaceuticals Inc 0.2
Oric Pharmaceuticals Inc 0.1
CG Oncology Inc 0.1
CRISPR Therapeutics AG 0.1
Eton Pharmaceuticals Inc 0.1
Xencor Inc 0.0
Aquinox Pharmaceuticals Inc 0.0
View All
Holdings by Sector ($B)
5.04.03.02.01.00.02015201920232027
Type Form D Funds Date Sold AUM
VC EcoR1 Venture Opportunity Fund LP [2019-08-29] 5.5 M 65.4 M
Filed 2020-05-08 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $2,000,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
HF EcoR1 Special Opportunity Fund II LP [2016-03-29] 0.6 M
Filed 2015-11-06 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF EcoR1 Special Opportunity Fund I LP [2015-03-30] 8.8 M
Filed 2015-02-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF EcoR1 Capital Fund LP [2014-03-25] 117.8 M 229.0 M
Filed 2026-01-22 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $25,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF EcoR1 Capital Fund Qualified LP [2014-03-25] 1,811.4 M 3,130.2 M
Filed 2026-01-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $25,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 5 3.4
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 5 3.4
By Discretionary
Discretionary 5 3.4
Non-Discretionary 0 0.0
Total 5 3.4
By Non-United States Persons
Non-United States Persons 0.7
United States Persons 2.8
Total 5 3.4
Form D Directors Role # Filings # Firms 2011 - 2026
Oleg Nodelman Executive Officer 14 3
Scott Perlen Executive Officer 8 2
Sarah Marriott Executive Officer 7 2
EcoR1 Capital LLC Executive Officer 5 2
Biotech Opportunity GP LLC Executive Officer 2 2
EDGAR Form CIK 2011 - 2026
13F-HR [0001587114]
3 [0001587114]
4 [0001587114]
SC 13D [0001587114]
SC 13G [0001587114]
Form 13D/13G Filer Form 13D/13G Subject Filed
EcoR1 Capital LLC Alto Neuroscience Inc [2026-07-20]
EcoR1 Capital LLC Fulcrum Therapeutics Inc [2026-06-25]
EcoR1 Capital LLC Fulcrum Therapeutics Inc [2026-06-25]
EcoR1 Capital LLC Eloxx Pharmaceuticals Inc [2026-06-16]
EcoR1 Capital LLC First Tracks Biotherapeutics Inc [2026-04-22]
EcoR1 Capital LLC Aktis Oncology Inc [2026-01-20]
EcoR1 Capital LLC Mereo Biopharma Group PLC [2026-01-09]
EcoR1 Capital LLC IBIO Inc [2025-12-17]
EcoR1 Capital LLC Oric Pharmaceuticals Inc [2025-08-05]
EcoR1 Capital LLC Hillevax Inc [2025-07-24]
View All
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund
LEI254900G27UH5KKYMY240
Form 3/4/5 Subject 2011 - 2026
EcoR1 Capital LLC
Atara Biotherapeutics Inc
First Tracks Biotherapeutics Inc
Nodelman OLEG
Aktis Oncology Inc
Adaptimmune Therapeutics PLC
Zymeworks Inc
iTeos Therapeutics Inc
Prothena Corp Public Ltd Co
Anaptysbio Inc
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Aktis Oncology Inc AKTS
Common Stock
2026-01-12 Buy 2,077,779 $18.00 37,400,022
Aktis Oncology Inc AKTS
Common Stock
2026-01-12 Conversion 128,506
Aktis Oncology Inc AKTS
Common Stock
2026-01-12 Conversion 202,862
Aktis Oncology Inc AKTS
Common Stock
2026-01-12 Conversion 2,270,879
Aktis Oncology Inc AKTS
Common Stock
2026-01-12 Buy 144,443 $18.00 2,599,974
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
2026-01-12 Conversion 9,913,810
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
2026-01-12 Conversion 997,299
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
2026-01-12 Conversion 488,891
Aktis Oncology Inc AKTS
Series B Redeemable Convertible Preferred Stock · derivative
2026-01-12 Conversion 2,397,500
Aktis Oncology Inc AKTS
Class A Common Stock · derivative
2026-01-12 Conversion 965,190
Aktis Oncology Inc AKTS
Class A Common Stock · derivative
2026-01-12 Conversion 86,222
Aktis Oncology Inc AKTS
Series B Redeemable Convertible Preferred Stock · derivative
2026-01-12 Conversion 102,500
Adaptimmune Therapeutics PLC ADAP
Ordinary Shares
2025-07-30 Sell 27,433,338 $0.10 2,743,334
Adaptimmune Therapeutics PLC ADAP
Ordinary Shares
2025-07-29 Sell 2,687,460 $0.10 268,746
Adaptimmune Therapeutics PLC ADAP
Ordinary Shares
2025-07-28 Sell 33,931,740 $0.11 3,732,491
Zymeworks Inc ZYME
Pre-Funded Warrants (right to acquire) · derivative
2025-06-26 Option exercise 5,086,521 $0.00
Zymeworks Inc ZYME
Common Stock
2025-06-26 Option exercise 5,086,480 $0.00
Zymeworks Inc ZYME
Common Stock
2025-06-26 Tax withheld 41 $12.71 521
Zymeworks Inc ZYME
Common Stock
2025-05-19 Buy 5,919 $11.78 69,726
Zymeworks Inc ZYME
Common Stock
2025-05-15 Buy 49,502 $11.43 565,808
showing 20 of 159 most recent transactions
Comparable Firms State AUM
Marble Bar Asset Management LLP
3,568.3 M
JAHD Management Company LLC
MA 3,557.9 M
Burkehill Global Management LP
NY 3,536.9 M
Dragonfly Digital Management LLC
CA 3,437.5 M
Carronade Capital Management LP
CT 3,431.8 M
Caption Management LLC
OK 3,407.7 M
Lakewood Capital Management LP
NY 3,398.7 M
Invenomic Capital Management LP
MA 3,392.8 M
Atalan Capital Partners LP
NY 3,290.1 M
Verger Capital Management LLC
NC 3,283.7 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com